Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



Canada commits to R&D

04 Feb 04

By 2010 Canada aims to become one of the top 5 countries in the world in terms of industrial R&D performance. Its pharmaceutical and biotech sectors, which are already key contributors to the economy, look set to prosper.
Dr Faiz Kermani and Dr Rebecca Gittins

Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

03 Feb 04

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.
Jennifer McGinnis


20 Jan 04

a Bristol based Biochemical Company, says it has invented a new sprayable antibacterial disinfectant agent, to be launched under the name of D-Stroy, that can kill the hospital superbug MRSA and TB.
Daisy Norman

Why Pharmaceutical R&D investment can pay off

19 Jan 04

Obtaining a benefit from pharmaceutical R&D investment requires long-term planning and a consideration of how the commercial and technological environment in which the industry operates might change.
Dr Faiz Kermani

Can Pharma Reign in Spain? – Part 2

12 Jan 04

Spain has a buoyant pharmaceutical market, but it is also a growing centre for pharmaceutical R&D. Industry figures show that there has been a rapid rise in R&D investment in the country since the early 1990s.
Dr Faiz Kermani

Emerging Drug Discovery Targets (18th December 2003)

05 Jan 04

This edition of features new generation oncolytic viruses from Cell Genesys active against colorectal cancer cells; a p38 MAPK inhibitor for the treatment of rheumatoid arthritis from Fujisawa; data describing the anti-angiogenic activity of bisphosphonates in cancer models; a new JAK3 inhibitor from Pfizer for transplant rejection; and an integrin antagonist from Merck for the treatment of osteoporosis. As usual updates on industrial advances and licensing opportunities are provided.

2nd Annual Pediatric Drug Development

02 Jan 04

Pharmaceutical Education Associates' proud to present our 2nd Annual Pediatric Drug Development conference, slated for February 23-24, 2004 in Washington, D.C. Don't miss your chance to hear about the key issues impacting pediatric drug development today! For more information call us at 800-686-2276 visit
Feliz Casanova

Can Pharma Reign in Spain? – Part 3

23 Dec 03

The growth of the pharmaceutical market and an improvement in the conditions for R&D, have led to increased emphasis being placed on Spain by pharmaceutical companies. Measures have also been taken by the Spanish government to directly boost pharmaceutical R&D innovation.
Dr Faiz Kermani

Can Pharma Reign in Spain? Part 1

23 Dec 03

As with most major pharmaceutical markets, patient demand for the latest innovative products has helped drive growth of the Spanish pharmaceutical market.
Dr Faiz Kermani

Pharma NewsBytes: Selected pharma press releases - Dec 1st-17th

18 Dec 03

Pharma NewsBytes selects out what LeadDiscovery considers as being some of the most interesting press releases to have appeared on their DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of Alzheimer's disease; advances in autoimmune diseases and inflammatory disorders; and news from the 26th Annual San Antonio Breast Cancer Symposium

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.